GLP-1 Signaling in Truncally Vagotomized Subjects

Last updated: May 20, 2018
Sponsor: University of Copenhagen
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT02940184
UC/RH-vago-GLP-1
  • Ages > 18
  • Male
  • Accepts Healthy Volunteers

Study Summary

Investigation of the importance of vagal signaling for the glucohomeostatic effects of GLP-1. The study will include physiological studies of truncally vagotomized participants and matched controls.

Eligibility Criteria

Inclusion

Truncally vagotomized individuals: Inclusion Criteria:

  • Normal fasting plasma glucose

  • Normal haemoglobin concentration

  • Cardiaresection with a pyloroplasty

  • Informed consent

Exclusion

Exclusion Criteria:

  • Diabetes mellitus

  • Disposition for diabetes mellitus

  • Intestinal disease (apart from cardia resection+pyloroplasty)

  • Disposition of inflammatory bowel disease

  • Intestinal resection (apart from cardia resection+pyloroplasty)

  • Body mass index (BMI) > 27,5 kg/m2

  • Tobacco use

  • Nephropathy (se-creatinine> 130 µM and/or albuminuria)

  • Liver disease (ALAT and/or ASAT >2 × refference value)

  • known heart condition

  • medicinal use, that may not be paused for 12 hours

  • Obstipation

  • swallowing difficulties

  • previous problems with intestinal tube placement

  • Latex allergy

  • Fructose malabsorption

  • Known diseases in the pharynx

  • Previous facial or cranial fractures

  • Sinusitis

  • Bleeding diathesis Matched controls: Inclusion Criteria:

  • Normal fasting plasma glucose

  • Normal haemoglobin concentration

  • Informed consent Exclusion Criteria:

  • Cardiaresection with a pyloroplasty

  • Diabetes mellitus

  • Disposition for diabetes mellitus

  • Intestinal disease (apart from cardia resection+pyloroplasty)

  • Disposition of inflammatory bowel disease

  • Intestinal resection tarmresektion (apart from cardia resection+pyloroplasty)

  • Body mass index (BMI) > 27,5 kg/m2

  • Tobacco use

  • Nephropathy (se-creatinine> 130 µM and/or albuminuria)

  • Liver disease (ALAT and/or ASAT >2 × refference value)

  • known heart condition

  • medicinal use, that may not be paused for 12 hours

  • Obstipation

  • swallowing difficulties

  • previous problems with intestinal tube placement

  • Latex allergy

  • Fructose malabsorption

  • Known diseases in the pharynx

  • Previous facial or cranial fractures

  • Sinusitis

  • Bleeding diathesis

Study Design

Total Participants: 24
Study Start date:
June 01, 2016
Estimated Completion Date:
October 31, 2018

Connect with a study center

  • Department of Surgery C, Rigshospitalet

    Copenhagen, 2100
    Denmark

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.